1 of 16

Laboratory Committee meeting

Oct 17, 2024

2 of 16

Welcome to the Laboratory Committee Meeting

Please remain muted unless speaking.

Improve bandwidth

by closing excess windows & apps.

Agendas and other documentation can be found at loinc.org/committee/laboratory

If you have any issues or questions, please contact us at labcommittee@loinc.org

​

Submit questions

via the Q&A function

at any time.

3 of 16

Agenda

Time

Topic

Action

Lead(s)

9:00-9:05

Welcome

Informational

Pam Banning

9:05-9:10

2024 LOINC Conference synopsis

Informational

Pam Banning

9:10-9:15

SHIELD - Update

Informational

Andrea Pitkus

9:15-9:30

-LOINC Forum

-HDS Requests

Informational/Discussion

Pam Banning/Eza Hafeza/All

9:30-9:40

DRUG/TOX Method Updates

​

Discussion

Pam Banning/All

​

9:40-9:55

Afew questions for clarification:

-IFCC (calibrators)

-Antibiotics XXX

Informational

Pam Banning

10:00

Closing and adjourn

Informational

Pam Banning

4 of 16

Welcome

​

1-Welcome and Introduction

5 of 16

2024 LOINC Conference

2024 LOINC Conference synopsis

​

6 of 16

SHIELD Update

By

Andrea Pitkus

​

SHIELD Home Page URL here

7 of 16

Forum requests/HDS Requests

Forum Requests

​

i..https://forum.loinc.org/t/flow-cytometry-cd19-cells-per-100-lymphocytes-100-cells/1838

​

ii. https://forum.loinc.org/t/loinc-and-microbiological-diagnostics-naa/1856/2

​

​

HDS Requests

​

  • Daratumamub Interference: sample/system determination

​

​

​

7

8 of 16

HDS questions

​

Resulting from RI/SCT collaborative work:

  • IFCC method: follow up
  • Amphetamine versus Amphetamines: follow up and comments from Anil

​

HSD Method

  • Sero-conversion (TBD)pending information from requester

​

​

Questions resulting from RI/SCT meeting

​

9 of 16

Submission request: Daratumamub Interference

•A submission request to create a code related to Daratumamub interference (ARUP Labs)

•There is no past instance of a similar request or Loinc code satisfying criteria

​

10 of 16

Submission request: Daratumamub Interference

​

https://www.elsevier.es/en-revista-medicina-universitaria-304-articulo-the-use-dtt-in-resolution-S1665579617300790

​

"Daratumumab (DARA) is a medication that in 2016 proved its efficacy and safety in the treatment of multiple myeloma. This product, based on a monoclonal antibody, technically generates an interference in most blood compatibility tests, artificially producing high blood pan-reactivity and incompatibility.......We adopted the use of dithiothreitol (or DTT) to treat the red blood cells of the possible blood donors for the patient, thus achieving the elimination of this technical discrepancy and the adequate, safe and timely selection of this blood component."

11 of 16

Submission request: Daratumamub Interference

•In this request the donor blood has been treated with DTT to avoid Daratumamub interference incompatibility

•Two samples(system): Donor Whole bld or patient ser?

•DTT is a compound, not a known method.(DTT is used to treat red blood cells (RBCs) to denature or modify blood group antigens)

​

​

12 of 16

13 of 16

14 of 16

15 of 16

16 of 16

Next Steps

​

  • Other topics

​

  • Next scheduled meeting : Nov 21, 2024 , 9:00-10:00 am ET

​

​

​

​

​

Agendas and other documentation can be found at loinc.org/committee/laboratory

If you have any issues or questions, please contact us at labcommittee@loinc.org